Transdermal Delivery of Ruxolitinib Through CO 2 Ablative Laser ‐Assisted Silk Nanovehicle System for Improved Melanocyte Recovery in Vitiligo
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202504458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Xue Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Vitiligo, Melanocytes, Nanoparticles, Pyrazoles. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Taian Scientific Innovation Development Foundation.
Abstract (Originalsprache)
Vitiligo, an autoimmune skin disorder, is characterized by the loss of melanocytes, resulting in significant skin depigmentation. Ruxolitinib (RUX), which could target the JAK‐STAT signaling pathway, plays a crucial role in vitiligo treatment but faces great challenges in transdermal delivery. Here, we developed RUX‐laden silk fibroin nanoparticles to achieve transdermal delivery with the assistance of a CO 2 ablative laser. In vitro assays demonstrated that the RUX‐laden silk nanoparticles significantly inhibited the secretion of CXCL9 and CXCL10, and the phosphorylation of AKT2 and STAT3, indicating effective modulation of the JAK‐STAT pathway. The RUX‐laden silk nanoparticles exhibited excellent transdermal delivery capacity comparable to the Opzelura cream, which was further improved through a laser‐assisted strategy. In vivo studies revealed that the transdermally delivered RUX‐laden nanoparticles exhibited better skin toleration and significantly reduced the expression of multiple inflammatory cytokines such as CXCL9, CXCL10, IFN‐γ and TNF‐α, bringing substantial melanocyte recovery. The findings underscore the potential of silk‐based delivery systems in enhancing therapeutic efficacy against vitiligo, which would improve pigmentation restoration and inflammation modulation in skin disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Dermatology and Venereology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.
- Taian City Central Hospital, Tai An, China.
- Institutes for Translational Medicine, Soochow University, Suzhou, China.
- National Engineering Laboratory for Modern Silk & Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, China.
ORCID-Profile: Qiang Lu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Taian Scientific Innovation Development Foundation
Zitieren
APA
Wang, X., Wang, Q., Yang, Y., Song, D., Xiao, L., Zhang, Z., & Lu, Q. (2026). Transdermal Delivery of Ruxolitinib Through CO 2 Ablative Laser ‐Assisted Silk Nanovehicle System for Improved Melanocyte Recovery in Vitiligo. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202504458
Vancouver
Wang X, Wang Q, Yang Y, Song D, Xiao L, Zhang Z, et al. Transdermal Delivery of Ruxolitinib Through CO 2 Ablative Laser ‐Assisted Silk Nanovehicle System for Improved Melanocyte Recovery in Vitiligo. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202504458
BibTeX
@article{Wang2026,
author = {Wang, Xue and Wang, Qirui and Yang, Yan and Song, Dawei and Xiao, Liying and Zhang, Zhen and Lu, Qiang},
title = {Transdermal Delivery of Ruxolitinib Through CO 2 Ablative Laser ‐Assisted Silk Nanovehicle System for Improved Melanocyte Recovery in Vitiligo},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202504458}
}
EUVIMED